Historical Valuation
WORK Medical Technology Group Ltd (WOK) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of WORK Medical Technology Group Ltd (WOK) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.18
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
WORK Medical Technology Group Ltd (WOK) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 2.39 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 2.39, the current P/B ratio is about -100.00% higher. WORK Medical Technology Group Ltd (WOK) has a Forward Free Cash Flow (FCF) yield of approximately -54907.72%. Compared to its 3-year average FCF yield of -1484.49%, the current FCF yield is approximately 3598.75% lower. Relative to its 5-year average FCF yield of -1484.49% , the current FCF yield is about 3598.75% lower.
P/B
Median3y
2.39
Median5y
2.39
FCF Yield
Median3y
-1484.49
Median5y
-1484.49
Competitors Valuation Multiple
AI Analysis for WOK
The average P/S ratio for WOK competitors is 0.22, providing a benchmark for relative valuation. WORK Medical Technology Group Ltd Corp (WOK.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for WOK
1Y
3Y
5Y
Market capitalization of WOK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of WOK in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is WOK currently overvalued or undervalued?
WORK Medical Technology Group Ltd (WOK) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of WORK Medical Technology Group Ltd (WOK) is between to according to relative valuation methord.
What is WORK Medical Technology Group Ltd (WOK) fair value?
WOK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of WORK Medical Technology Group Ltd (WOK) is between to according to relative valuation methord.
How does WOK's valuation metrics compare to the industry average?
The average P/S ratio for WOK's competitors is 0.22, providing a benchmark for relative valuation. WORK Medical Technology Group Ltd Corp (WOK) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for WORK Medical Technology Group Ltd (WOK) as of Jan 10 2026?
As of Jan 10 2026, WORK Medical Technology Group Ltd (WOK) has a P/B ratio of 0.00. This indicates that the market values WOK at 0.00 times its book value.
What is the current FCF Yield for WORK Medical Technology Group Ltd (WOK) as of Jan 10 2026?
As of Jan 10 2026, WORK Medical Technology Group Ltd (WOK) has a FCF Yield of -54907.72%. This means that for every dollar of WORK Medical Technology Group Ltd’s market capitalization, the company generates -54907.72 cents in free cash flow.
What is the current Forward P/E ratio for WORK Medical Technology Group Ltd (WOK) as of Jan 10 2026?
As of Jan 10 2026, WORK Medical Technology Group Ltd (WOK) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of WORK Medical Technology Group Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for WORK Medical Technology Group Ltd (WOK) as of Jan 10 2026?
As of Jan 10 2026, WORK Medical Technology Group Ltd (WOK) has a Forward P/S ratio of 0.00. This means the market is valuing WOK at $0.00 for every dollar of expected revenue over the next 12 months.